Insights - BIO

Areas of Work

	House Moves to Shore Up Nation’s Biodefenses By Passing BARDA Bill Sep 28 2006 WASHINGTON, D.C. (September 28, 2006) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today praised the U.S. House of Representatives for unanimously passing the ‘...
	BIO Joins Coalition to Strengthen FDA Sep 25 2006 Echoes Call For Increased Public Support
	BIO Applauds Passage of BARDA Bill Sep 22 2006 WASHINGTON, D.C. (September 22, 2006) -- Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding passage earlier this week of the ‘...
	Greenwood Releases Statement on IOM Drug Safety Document Sep 22 2006 WASHINGTON, D.C. (September 22, 2006) – Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement in initial response to release of ...
	Georgia Poll Reveals Broad Support for Stem Cell Research Sep 21 2006 WASHINGTON, D.C. (September 21, 2006) -- A statewide poll recently conducted in Georgia demonstrates that a significant majority of Georgians support embryonic stem cell research and...
	Milken Institute Study Confirms Vital Role of Technology Transfer in Biotechnology Globally, Says BIO Sep 20 2006 The Milken Institute study released today entitled “Mind-to-Market: A Global Analysis of University Biotechnology Technology Transfer and Commercialization” reaffirms the critical role of technology transfer in the development of the biotechnology industry worldwide, said Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood.
	BIO Statement on Senate Committee's Approval of the Nomination of von Eschenbach as FDA Commissioner Sep 20 2006 WASHINGTON, D.C. (September 20, 2006) -- Jim Greenwood, president of the Biotechnology Industry Organization (BIO), issued the following statement on the approval by the Senate...
	BIO Submits Comments Urging SEC to Ease Sarbanes-Oxley Burdens Sep 13 2006 Jim Greenwood issued the following remarks regarding comments submitted Tuesday by BIO and a group of organizations representing high-growth industries to the Securities and Exchange Commission (SEC) concerning burdens created by Section 404 (internal controls) of the Sarbanes-Oxley Act.
	Acting FDA Commissioner to Present Keynote Address at BIO Mid-America VentureForum 2006 Sep 8 2006 WASHINGTON, D.C. (September 8, 2006) -- Andrew C. von Eschenbach, M.D., acting commissioner of the Food and Drug Administration (FDA), will present a keynote address at 12:30-2 p.m. on Tuesday...
	Advance Media Registration for BIO InvestorForum 2006 Now Available Online Sep 6 2006 WASHINGTON, D.C. (September 6, 2006) -- Media registration is now available for BIO InvestorForum 2006, to be held October 18-19, 2006 at the Palace Hotel in San Francisco. Hosted by the...